Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2018

Open Access 01-12-2018 | Research

A multi-center nested case-control study on hospitalization costs and length of stay due to healthcare-associated infection

Authors: Yu Lü, Min Hong Cai, Jian Cheng, Kun Zou, Qian Xiang, Jia Yu Wu, Dao Qiong Wei, Zhong Hua Zhou, Hui Wang, Chen Wang, Jing Chen

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2018

Login to get access

Abstract

Background

In 2018, the Chinese government demanded nationwide implementation of medical insurance payment methods based on Single-Disease Payment (SDP), but during the operation process the medical insurance system did not fully consider the extra economic burden caused by healthcare-associated infection (HAI). HAIs can prolong the length of stay and increase the hospitalization costs, but only a few studies have been conducted in Sichuan province, China. We evaluated the hospitalization costs and length of stay due to HAI in Sichuan province based on the prevalence survey, and provided data reference for China’s medical insurance reform.

Methods

In the hospitals surveyed on the prevalence of HAI, a multi-center nested case-control study was performed by a paired method. The study period was from 6 September 2016 to 30 November 2016. Binary outcomes were tested using χ2 test, continuous outcomes were tested using Wilcoxon matched-pairs signed rank test, intra-group comparisons were tested using multiple linear regression analysis.

Results

A total of 225 pairs/450 patients were selected in 51 hospitals, and 170 pairs/350 patients were successfully matched. The case fatality rate was 5.14% for the HAIs patients and 3.43% for non-HAs patients, there was no significant difference (χ2 = 0.627, P = 0.429); the median length of stay in patients with HAIs was 21 days, longer than that of patients with non-HAI 16 days, the median of the difference between matched-pairs was 5 days, the difference was statistically significant (Z = 4.896, P = 0.000). The median hospitalization costs of patients with HAI were €1732.83, higher than that of patients with non-HAI €1095.29, the median of the difference between matched-pairs were €431.34, the difference was statistically significant (Z = 6.413, P = 0.000). Multiple linear regression results showed that HAIs at different sites have caused different economic burdens, but in different economic regions, the difference was not statistically significant.

Conclusions

In Sichuan, the hospitalization costs and length of stay caused by HAI should be given special attention in the current medical insurance reform. The proportion and scope of medical payment for patients with HAI at different sites should be different. Efforts need to be taken to incentivize reduction of HAI rates which will reduce hospitalization costs and length of stay.
Literature
2.
go back to reference Di X. The development of specific disease payment and its key issues of management. Chinese Health Resources. 2018;21:27–31. Di X. The development of specific disease payment and its key issues of management. Chinese Health Resources. 2018;21:27–31.
3.
go back to reference LIU Zhi-jian. Study on the Effect of New Health Payment Scheme on Medical Costs. D. University of Science and Technology of China (2017). LIU Zhi-jian. Study on the Effect of New Health Payment Scheme on Medical Costs. D. University of Science and Technology of China (2017).
4.
go back to reference Allegranzi B, Bagheri NS, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228.CrossRefPubMed Allegranzi B, Bagheri NS, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228.CrossRefPubMed
5.
go back to reference Guo C, Liu YH, Tian DS. Statistical research on direct economic loss due to nosocomial infections. Chinese Journal of Nosocomiology. 2012;22(8):1651–3. Guo C, Liu YH, Tian DS. Statistical research on direct economic loss due to nosocomial infections. Chinese Journal of Nosocomiology. 2012;22(8):1651–3.
6.
go back to reference Vrijens F, Hulstaert F, Sande SVD, et al. Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs. J Hosp Infect. 2010;75(3):158.CrossRefPubMed Vrijens F, Hulstaert F, Sande SVD, et al. Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs. J Hosp Infect. 2010;75(3):158.CrossRefPubMed
7.
go back to reference Gabriel L, Beriot-Mathiot A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect. 2014;88(1):12.CrossRefPubMed Gabriel L, Beriot-Mathiot A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect. 2014;88(1):12.CrossRefPubMed
10.
go back to reference Liuyi LI. New technique and progress of prevention and control of healthcare-associated infection. West China Medicine. 2018;33(3):240–43. Liuyi LI. New technique and progress of prevention and control of healthcare-associated infection. West China Medicine. 2018;33(3):240–43.
13.
go back to reference Ministry of Health P.R. China. WS/T 312–2009.Standard for nosocomial infection surveillance. Beijing: People's Medical Publishing House; 2009. Ministry of Health P.R. China. WS/T 312–2009.Standard for nosocomial infection surveillance. Beijing: People's Medical Publishing House; 2009.
14.
go back to reference Judd WR, Ratliff PD, Hickson RP, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control. 2016;44(11):1275–9.CrossRefPubMed Judd WR, Ratliff PD, Hickson RP, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control. 2016;44(11):1275–9.CrossRefPubMed
15.
go back to reference Marta R, Pietro C, Roser T, et al. Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona. Plos One. 2016;11(4):e0153076.CrossRef Marta R, Pietro C, Roser T, et al. Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona. Plos One. 2016;11(4):e0153076.CrossRef
16.
go back to reference Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro surveillance. 2016;21(33):1–12. Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro surveillance. 2016;21(33):1–12.
17.
go back to reference Vasudevan A, Memon BI, Mukhopadhyay A, et al. The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study. Antimicrobial Resistance and Infection Control. 2015;4(1):3.CrossRefPubMedPubMedCentral Vasudevan A, Memon BI, Mukhopadhyay A, et al. The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study. Antimicrobial Resistance and Infection Control. 2015;4(1):3.CrossRefPubMedPubMedCentral
18.
go back to reference Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12(1):122.CrossRefPubMedPubMedCentral Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12(1):122.CrossRefPubMedPubMedCentral
19.
go back to reference Wu AH. Economicevaluation onthe costs of healthcareassociated infection. Chinese Journal of Infection Control. 2016;5(3):193–7. Wu AH. Economicevaluation onthe costs of healthcareassociated infection. Chinese Journal of Infection Control. 2016;5(3):193–7.
21.
go back to reference Zhang XJ, Qiu TF. Application of incentive mechanism in control of nosocomial infections. Chinese Journal of Nosocomiology. 2012;22(5):1001–2. Zhang XJ, Qiu TF. Application of incentive mechanism in control of nosocomial infections. Chinese Journal of Nosocomiology. 2012;22(5):1001–2.
22.
go back to reference Qiang FU, Guo YH. National strategy for nosocomial infection control in new era. Chinese Journal of Nosocomiology. 2013;23(20):4861–4. Qiang FU, Guo YH. National strategy for nosocomial infection control in new era. Chinese Journal of Nosocomiology. 2013;23(20):4861–4.
23.
go back to reference Schulgen G, Kropec A, Kappstein I, et al. Estimation of extra hospitalization stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol. 2000;53(4):409–17.CrossRefPubMed Schulgen G, Kropec A, Kappstein I, et al. Estimation of extra hospitalization stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol. 2000;53(4):409–17.CrossRefPubMed
24.
go back to reference Barnett AG, Beyersmann J, Allignol A, et al. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research. 2011;14(2):381.CrossRef Barnett AG, Beyersmann J, Allignol A, et al. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research. 2011;14(2):381.CrossRef
Metadata
Title
A multi-center nested case-control study on hospitalization costs and length of stay due to healthcare-associated infection
Authors
Yu Lü
Min Hong Cai
Jian Cheng
Kun Zou
Qian Xiang
Jia Yu Wu
Dao Qiong Wei
Zhong Hua Zhou
Hui Wang
Chen Wang
Jing Chen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2018
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-018-0386-1

Other articles of this Issue 1/2018

Antimicrobial Resistance & Infection Control 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.